Dirk Theile

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9441429/publications.pdf

Version: 2024-02-01

49	762	516215 16	552369 26
papers	citations	h-index	g-index

49	49	49	1266
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. Biomedicines, 2022, 10, 1.	1.4	17
2	How to avoid misinterpretation of dual reporter gene assay data affected by cell damage. Archives of Toxicology, 2022, 96, 2501-2510.	1.9	3
3	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. British Journal of Clinical Pharmacology, 2021, 87, 858-874.	1.1	9
4	A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19. Cytokine, 2021, 138, 155399.	1.4	2
5	Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes. Pharmaceutics, 2021, 13, 808.	2.0	3
6	Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1621-1632.	1.4	17
7	In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. European Journal of Pharmaceutical Sciences, 2021, 162, 105826.	1.9	5
8	Regulation of PXR Function by Coactivator and Corepressor Proteins: Ligand Binding Is Just the Beginning. Cells, 2021, 10, 3137.	1.8	6
9	Reporter cell assay-based functional quantification of TNF-Î±-antagonists in serum â€“ a proof-of-principle study for adalimumab. Analytical Biochemistry, 2020, 596, 113646.	1.1	3
10	Bosentan enhances inÂvitro bortezomib's antiâ€proliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade. British Journal of Haematology, 2019, 184, 1052-1055.	1.2	0
11	Pharmacodynamic monitoring using biomarkers to individualize pharmacotherapy. Biomarkers in Medicine, 2019, 13, 393-408.	0.6	2
12	Given the Data of Hommers and Colleagues, Valproic Acid Is Not an Unequivocal Inducer of Clozapine Metabolism. Journal of Clinical Psychopharmacology, 2019, 39, 419-420.	0.7	1
13	Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 461-466.	1.4	0
14	Methadone against cancer: Lost in translation. International Journal of Cancer, 2018, 143, 1840-1848.	2.3	14
15	The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma. PLoS ONE, 2018, 13, e0193242.	1.1	8
16	Clementine juice has the potential for drug interactions â€“ In vitro comparison with grapefruit and mandarin juice. European Journal of Pharmaceutical Sciences, 2017, 97, 247-256.	1.9	38
17	Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient. Cancer Chemotherapy and Pharmacology, 2017, 80, 71-79.	1.1	5
18	Impact of enzalutamide and its main metabolite Nâ€desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharmaceutics and Drug Disposition, 2017, 38, 517-525.	1.1	18

#	Article	IF	Citations
19	t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit. Cellular Signalling, 2017, 40, 53-61.	1.7	9
20	Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 49-59.	1.4	6
21	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncology Letters, 2017, 14, 3185-3192.	0.8	6
22	Under-Reported Aspects of Platinum Drug Pharmacology. Molecules, 2017, 22, 382.	1.7	15
23	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Letters, 2016, 376, 165-172.	3.2	50
24	Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assays. Analytical Biochemistry, 2016, 509, 124-129.	1.1	4
25	Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 1091-1101.	1.4	5
26	Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. Toxicology Letters, 2016, 242, 47-52.	0.4	6
27	Comment on â€œSweat but no gainâ€• Inhibiting proliferation of multidrug resistant cancer cells with â€œErsatzdrogesâ€• International Journal of Cancer, 2015, 136, 2241-2242.	2.3	0
28	Obatoclax as a perpetrator in drugâ€“drug interactions and its efficacy in multidrug resistance cell lines. Journal of Pharmacy and Pharmacology, 2015, 67, 1575-1584.	1.2	5
29	Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine, 2015, 49, 842-853.	1.1	23
30	Desmethyl bosentan displays a similar inÂvitro interaction profile as bosentan. Pulmonary Pharmacology and Therapeutics, 2015, 30, 80-86.	1.1	4
31	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemotherapy and Pharmacology, 2015, 75, 281-291.	1.1	22
32	Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1141-1150.	1.4	12
33	Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity. Analytical Biochemistry, 2015, 471, 23-25.	1.1	2
34	Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e108908.	1.1	22
35	Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro. Pharmaceutics, 2014, 6, 632-650.	2.0	18
36	Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biology and Therapy, 2014, 15, 436-442.	1.5	7

#	Article	IF	Citations
37	Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation. Toxicology Letters, 2014, 225, 43-47.	0.4	28
38	Deceptive argumentation against diagnostic microdosing of anticancer drugs. International Journal of Cancer, 2014, 135, 1753-1754.	2.3	1
39	What, if all alerts were specific â€“ Estimating the potential impact on drug interaction alert burden. International Journal of Medical Informatics, 2014, 83, 285-291.	1.6	75
40	In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. Journal of Pharmacy and Pharmacology, 2013, 65, 1518-1525.	1.2	13
41	Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochemical Pharmacology, 2013, 85, 265-273.	2.0	50
42	Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2013, 37, E17-22.	1.4	17
43	Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. Cancer Chemotherapy and Pharmacology, 2013, 71, 1335-1343.	1.1	16
44	Regulation of Biotransformation Systems and ABC Transporters by Benznidazole in HepG2 Cells: Involvement of Pregnane X-Receptor. PLoS Neglected Tropical Diseases, 2012, 6, e1951.	1.3	20
45	Cellular Pharmacokinetic/Pharmacodynamic Relationship of Platinum Cytostatics in Head and Neck Squamous Cell Carcinoma Evaluated by Liquid Chromatography Coupled to Tandem Mass Spectrometry. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 51-58.	1.3	11
46	Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 1025-1034.	1.4	8
47	Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head and Neck, 2011, 33, 959-968.	0.9	24
48	Impact of drug transporters on cellular resistance towards saquinavir and darunavir. Journal of Antimicrobial Chemotherapy, 2010, 65, 2319-2328.	1.3	75
49	Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochemical Pharmacology, 2009, 78, 1366-1373.	2.0	57